A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M ™

Conditions: Malaria,Falciparum Interventions: Biological: R21/Matrix M ™ (Group 1); Biological: R21/Matrix M™ (Group 2); Biological: R21/Matrix M™ (Group 3); Procedure: Fine needle aspiration (FNA) Sponsors: University of Oxford; Bill and Melinda Gates Foundation; University Hospitals Bristol and Weston NHS Foundation Trust Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials